Log in

NASDAQ:PDLIPDL BioPharma Earnings Date, Estimates & History

$3.33
+0.01 (+0.30 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.28
Now: $3.33▼
$3.47
50-Day Range
$2.97
MA: $3.25▼
$3.63
52-Week Range
$2.06
Now: $3.33▼
$3.86
Volume794,858 shs
Average Volume967,781 shs
Market Capitalization$388.11 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84

Earnings

PDL BioPharma (NASDAQ:PDLI) Earnings Information

PDL BioPharma last released its earnings results on May 7th, 2020. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of $0.05 by $0.31. The company had revenue of $6 million for the quarter. PDL BioPharma has generated $0.28 earnings per share over the last year. PDL BioPharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 5th, 2020 based off prior year's report dates.

PDL BioPharma Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PDL BioPharma (NASDAQ:PDLI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $-0.05 EPS

PDL BioPharma (NASDAQ PDLI) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/5/2020
(Estimated)		       
5/7/20203/31/2020$0.05($0.26)($0.10)$6.00 millionTranscript
3/11/202012/31/2019$0.05($0.48)$0.52($5.80) millionTranscript
11/6/2019Q3 2019$0.04$0.08$0.32$44.17 millionN/A
8/7/2019Q2 2019$0.04$0.09$0.22($22.53) millionN/A
5/9/20193/31/2019$0.08$0.08$0.11$38.91 millionN/A
3/14/201912/31/2018$0.08$0.10$0.09$45.12 millionN/A
11/6/2018Q3$0.07$0.07($0.04)$67.90 millionN/A
8/8/2018Q2 2018$0.06$0.10$0.96$46.58 millionN/A
5/9/2018Q1 2018$0.06$0.08$0.15$38.52 millionN/A
3/8/2018Q4 2017$0.17$0.19$68.04 millionN/A
11/2/2017Q3 2017$0.13$0.14$0.14$61.86 million$62.75 millionN/A
8/3/2017Q2 2017$0.09$0.26$0.13$56.30 million$143.80 millionListen
5/3/2017Q1 2017$0.05$0.08$0.12$45.44 millionListen
11/3/2016Q3 2016$0.14$0.11$0.14$50.69 million$53.60 millionN/A
8/4/2016Q2 2016$0.10$0.09$0.15$33.46 million$21.00 millionN/A
5/4/2016Q1 2016$0.54$0.52$0.70$142.05 million$103.10 millionN/A
2/22/2016Q4 2015$0.58$0.61$0.61$149.20 million$178.10 millionListen
11/4/2015Q3 2015$0.73$0.42$0.42$164.80 million$124.60 millionN/A
8/5/2015Q2 2015$0.55$0.47$0.47$137.75 million$138.10 millionN/A
5/6/2015Q1 2015$0.58$0.50$0.50$140.80 million$149.71 millionN/A
2/23/2015Q4 2014$0.32$0.32$158.15 million$117.10 millionListen
11/10/2014Q3 2014$0.61$0.61$165.10 million$164.60 millionN/A
8/18/2014Q2 2014$0.55$0.52$0.52$134.07 million$162.80 millionListen
5/12/2014Q1 2014$0.51$0.47$0.50$130.93 million$139.70 millionN/A
3/3/2014Q4 2013$0.41$0.39$0.39$115.22 million$110.10 millionN/A
11/6/2013Q3 2013$0.39$0.36$0.36$97.09 million$97.30 millionN/A
8/8/2013Q2 2013$0.57$0.62$0.62$138.20 million$143.60 millionN/A
5/9/2013Q1 2013$0.38$0.36$0.36$91.69 million$91.80 millionListen
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionTranscript
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionN/A
8/2/2012$0.44$0.52N/A
5/3/2012$0.27$0.29N/A
2/23/2012$0.28$0.24N/A
11/9/2011$0.27$0.28N/A
7/27/2011$0.39$0.39N/A
4/27/2011$0.24$0.25N/A
2/28/2011$0.21$0.20N/A
11/10/2010Q3 2010$0.25$0.25$0.26N/A
7/28/2010Q2 2010$0.38$0.38$0.46N/A
4/29/2010Q1 2010$0.23$0.15$0.15N/A
3/2/2010Q4 2009$0.19$0.17$0.17N/A
10/28/2009Q3 2009$0.26$0.28$0.28N/A
7/30/2009Q2 2009$0.42$0.45$0.44N/A
5/7/2009Q1 2009$0.24$0.23$0.23N/A
3/2/2009Q4 2008$0.06$0.34$0.42N/A
11/6/2008Q3 2008$0.24$0.08($0.22)N/A
8/11/2008Q2 2008$0.21$0.36$0.48N/A
5/8/2008Q1 2008($0.01)($0.08)$0.28N/A
3/4/2008Q4 2007$0.15($0.01)$0.11N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 6/6/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.